[url="]DEXCOM[/url], INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of [url="]Dexcom U[/url], the
SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.Now in its fifth year, this marks the program's largest and most expansive roster to date, featuring 27 college athletes, 12 new and 15 returning, across 13 sports. The expansion is backed by new research showing that programs l.
[url="]DexCom, Inc.[/url] (NASDAQ: DXCM), the global leader in glucose biosensing, today released its âDexcom State of Type 2 Report: Global Access and Attitu
MILAN--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its “Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology” in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28-Oct. 2. The company also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk. Dexcom releases 2026 edition of its State of Type 2 Repo.
DexCom, Inc. (NASDAQ: DXCM - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-six ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twenty-one have issued a buy rating and two have